Drug–drug interactions involving combinations of antipsychotic agents with antidiabetic, lipid-lowering, and weight loss drugs

References

• Correll CU, Solmi M, Croatto G, et al. Mortality in people with schizophrenia: a systematic review and meta‐analysis of relative risk and aggravating or attenuating factors. World Psychiatry. 2022;21(2):248–271.
   PubMed Web of Science ®Google Scholar
• Laursen TM, Nordentoft M, Mortensen PB. Excess early mortality in schizophrenia. Annu Rev Clin Psychol. 2014;10(1):425–448.
   PubMedGoogle Scholar
• de Mooij LD, Kikkert M, Theunissen J, et al. Dying too soon: excess mortality in severe mental illness. Front Psychiatry. 2019;10:20–23.
   PubMed Web of Science ®Google Scholar
• Correll CU, Solmi M, Veronese N, et al., Prevalence, incidence and mortality from cardiovascular disease in patients with pooled and specific severe mental illness: a large-scale meta-analysis of 3,211,768 patients and 113,383,368 controls. World Psychiatry. 2017;16(2):163–180.
   PubMed Web of Science ®Google Scholar
• Heiberg IH, Jacobsen BK, Balteskard L, et al. Undiagnosed cardiovascular disease prior to cardiovascular death in individuals with severe mental illness. Acta Psychiatr Scand. 2019;139(6):558–571.
   PubMed Web of Science ®Google Scholar
• Ali S, Santomauro D, Ferrari AJ, et al. Excess mortality in severe mental disorders: a systematic review and meta-regression. J Psychiatr Res. 2022;149:97–105.
   PubMedGoogle Scholar
• Nielsen RE, Banner J, Jensen SE. Cardiovascular disease in patients with severe mental illness. Nat Rev Cardiol. 2021;18(2):136–145.
   PubMed Web of Science ®Google Scholar
• Fernández Guijarro S, Miguel García C, Pomarol-Clotet E, et al. Metabolic syndrome screening in people with severe mental illness: results from two Spanish community mental health centers. J Am Psychiatr Nurses Assoc. 2020;26(2):162–171.
   PubMed Web of Science ®Google Scholar
• Mariano A, Di Lorenzo G, Jannini TB, et al. Medical Comorbidities in 181 patients with bipolar disorder vs. schizophrenia and related psychotic disorders: findings from a single-center, retrospective study from an acute inpatients psychiatric unit. Front Psychiatry. 2021;12:1–9.
   Google Scholar
• Vancampfort D, Stubbs B, Mitchell AJ, et al., Risk of metabolic syndrome and its components in people with schizophrenia and related psychotic disorders, bipolar disorder and major depressive disorder: a systematic review and meta-analysis. World Psychiatry. 2015;14(3):339–347. .
   PubMed Web of Science ®Google Scholar
• Yang F, Ma Q, Liu J, et al. Prevalence and major risk factors of type 2 diabetes mellitus among adult psychiatric inpatients from 2005 to 2018 in Beijing, China: a longitudinal observational study. BMJ Open Diabetes Res Care. 2020;8(1):e000996.
   PubMed Web of Science ®Google Scholar
• Yang F, Ma Q, Ma B, et al. Dyslipidemia prevalence and trends among adult mental disorder inpatients in Beijing, 2005–2018: a longitudinal observational study. Asian J Psychiatr. 2021;57:102583.
   PubMed Web of Science ®Google Scholar
• Tan XW, Chan CYW, Lum AWM, et al. Association of cardiovascular metabolic risk factor measurements with psychiatric readmission among in-hospital patients with severe mental illness: a retrospective study. BMC Psychiatry. 2022;22(1):1–10.
   PubMed Web of Science ®Google Scholar
• Bernardo M, Cañas F, Banegas JR, et al. Prevalence and awareness of cardiovascular risk factors in patients with schizophrenia: a cross-sectional study in a low cardiovascular disease risk geographical area. Eur Psychiatry. 2009;24(7):431–441.
   PubMed Web of Science ®Google Scholar
• Ringen PA, Lund-Stenvold E, Andreassen OA, et al. Quality of clinical management of cardiometabolic risk factors in patients with severe mental illness in a specialist mental health care setting. Nord J Psychiatry. 2022 76(8) ;602–609.
   Web of Science ®Google Scholar
• Taub S, Hoshen M, Balicer R, et al. Metabolic predictors for mortality among patients treated with long-term clozapine – a longitudinal study. Eur Neuropsychopharmacol. 2020;41:63–69.
   PubMed Web of Science ®Google Scholar
• Willner K, Vasan S, Abdijadid S. Atypical antipsychotic agents. Treasure Island, FL: StatPearls. StatPearls Publishing; 2022.
   Google Scholar
• Solmi M, Murru A, Pacchiarotti I, et al. Safety, tolerability, and risks associated with first- and second-generation antipsychotics: a state-of-the-art clinical review. Ther Clin Risk Manag. 2017;13:757–777.
   PubMed Web of Science ®Google Scholar
• Haddad PM, Sharma SG. Adverse effects of atypical antipsychotics. CNS Drugs. 2007;21(11):911–936.
   PubMed Web of Science ®Google Scholar
• Woodhead C, Ashworth M, Broadbent M, et al. Cardiovascular disease treatment among patients with severe mental illness: a data linkage study between primary and secondary care. Br J Gen Pract. 2016;66(647):e374–e381.
   PubMed Web of Science ®Google Scholar
• Bernardo M, Rico-Villademoros F, García-Rizo C, et al. Real-world data on the adverse metabolic effects of second-generation antipsychotics and their potential determinants in adult patients: a systematic review of population-based studies. Adv Ther. 2021;38(5):2491–2512.
   PubMed Web of Science ®Google Scholar
• Cernea S, Dima L, Correll CU, et al., Pharmacological management of glucose dysregulation in patients treated with second-generation antipsychotics. Drugs. 2020;80(17):1763–1781. .
   PubMed Web of Science ®Google Scholar
• Lydon A, Vallely J, Tummon A, et al. Routine screening and rates of metabolic syndrome in patients treated with clozapine and long-acting injectable antipsychotic medications: a cross-sectional study. Ir J Psychol Med. 2021;38(1):40–48.
   PubMed Web of Science ®Google Scholar
• Schoretsanitis G, Dubath C, Grosu C, et al. Olanzapine‐associated dose‐dependent alterations for weight and metabolic parameters in a prospective cohort. Basic Clin Pharmacol Toxicol. 2022;130(4):531–541.
   PubMed Web of Science ®Google Scholar
• Buzea CA, Dima L, Correll CU, et al., Drug–drug interactions involving antipsychotics and antihypertensives. Expert Opin Drug Metab Toxicol. 2022;18(4):285–298.
   PubMed Web of Science ®Google Scholar
• Kanagasundaram P, Lee J, Prasad F, et al. Pharmacological interventions to treat antipsychotic-induced dyslipidemia in schizophrenia patients: a systematic review and meta analysis. Front Psychiatry. 2021;12:642403.
   PubMed Web of Science ®Google Scholar
• Sicras-Mainar A, Blanca-Tamayo M, Rejas-Gutiérrez J, et al. Metabolic syndrome in outpatients receiving antipsychotic therapy in routine clinical practice: a cross-sectional assessment of a primary health care database. Eur Psychiatry. 2008;23(2):100–108.
   PubMed Web of Science ®Google Scholar
• Correll CU, Frederickson AM, Kane JM, et al. Equally increased risk for metabolic syndrome in patients with bipolar disorder and schizophrenia treated with second-generation antipsychotics. Bipolar Disord. 2008;10(7):788–797.
   PubMed Web of Science ®Google Scholar
• Penninx BWJH, Lange SMM. Metabolic syndrome in psychiatric patients: overview, mechanisms, and implications. Dialogues Clin Neurosci. 2018;20(1):63–73.
   PubMed Web of Science ®Google Scholar
• Sud D, Laughton E, McAskill R, et al. The role of pharmacy in the management of cardiometabolic risk and metabolic syndrome in severe mental illness: a mixed methods review. Syst Rev. 2021;10(1). doi:10.1186/s13643-021-01586-9.
   Web of Science ®Google Scholar
• Ward M. Increasing psychiatrists’ role in addressing the cardiovascular health of patients with severe mental illness. Focus (Madison). 2021;19(1):24–30.
   Google Scholar
• Wishart DS, Feunang YD, Guo AC, et al. DrugBank 5.0: a major update to the DrugBank database for 2018. Nucleic Acids Res. 2018;46(D1):D1074–D1082.
   PubMed Web of Science ®Google Scholar
• Benet L. Changes in plasma protein binding have little clinical relevance. Clin Pharmacol Ther. 2002;71(3):115–121.
   PubMed Web of Science ®Google Scholar
• Siafis S, Tzachanis D, Samara M, et al. Antipsychotic drugs: from receptor-binding profiles to metabolic side effects. Curr Neuropharmacol. 2018;16(8):1210–1223.
   PubMed Web of Science ®Google Scholar
• Durst R, Leitersdorf E. A tail with a thorn in it: second-generation antipsychotics hand in hand with statins. Curr Atheroscler Rep. 2012;14(5):391–393.
   PubMed Web of Science ®Google Scholar
• Pillinger T, D’Ambrosio E, McCutcheon R, et al. Is psychosis a multisystem disorder? A meta-review of central nervous system, immune, cardiometabolic, and endocrine alterations in first-episode psychosis and perspective on potential models. Mol Psychiatry. 2019;24(6):776–794.
   PubMed Web of Science ®Google Scholar
• Pillinger T, Beck K, Stubbs B, et al. Cholesterol and triglyceride levels in first-episode psychosis: systematic review and meta-analysis. Br J Psychiatry. 2017;211(6):339–349.
   PubMed Web of Science ®Google Scholar
• Sirtori CR. The pharmacology of statins. Pharmacol Res. 2014;88:3–11.
   PubMed Web of Science ®Google Scholar
• Siwek M, Woroń J, Gorostowicz A, et al. Adverse effects of interactions between antipsychotics and medications used in the treatment of cardiovascular disorders. Pharmacol Rep. 2020;72(2):350–359.
   PubMed Web of Science ®Google Scholar
• Ojala K, Repo-Tiihonen E, Tiihonen J, et al. Statins are effective in treating dyslipidemia among psychiatric patients using second-generation antipsychotic agents. J Psychopharmacol. 2008;22(1):33–38.
   PubMed Web of Science ®Google Scholar
• Melkersson K, Dahl M-L. Adverse metabolic effects associated with atypical antipsychotics. Drugs. 2004;64(7):701–723.
   PubMed Web of Science ®Google Scholar
• Meltzer H. Marked elevations of serum creatine kinase activity associated with antipsychotic drug treatment. Neuropsychopharmacology. 1996;15(4):395–405.
   PubMed Web of Science ®Google Scholar
• Melli G, Chaudhry V, Cornblath DR. Rhabdomyolysis. Medicine (Baltimore). 2005;84(6):377–385.
   PubMed Web of Science ®Google Scholar
• Scelsa SN, Simpson DM, McQuistion HL, et al. Clozapine-induced myotoxicity in patients with chronic psychotic disorders. Neurology. 1996;47(6):1518–1523.
   PubMed Web of Science ®Google Scholar
• Rosebraugh CJ, Flockhart DA, Yasuda SU, et al. Olanzapine-induced rhabdomyolysis. Ann Pharmacother. 2001;35(9):1020–1023.
   PubMed Web of Science ®Google Scholar
• Botillo-Martin C, González-Pablos E. Rhabdomyolysis of multifactorial origin in schizophrenia. J Clin Psychopharmacol. 2018;38(3):261–263.
   PubMed Web of Science ®Google Scholar
• Tucker P. Liver toxicity with clozapine. Aust New Zeal J Psychiatry. 2013;47(10):975–976.
   PubMed Web of Science ®Google Scholar
• Platanić Arizanović L, Nikolić-Kokić A, Brkljačić J, et al. Effects of several atypical antipsychotics closapine, sertindole or ziprasidone on hepatic antioxidant enzymes: possible role in drug-induced liver dysfunction. J Toxicol Environ Heal Part A. 2021;84(4):173–182.
   PubMed Web of Science ®Google Scholar
• Domínguez-Jiménez JL, Puente-Gutiérrez JJ, Pelado-García EM, et al. Liver toxicity due to olanzapine. Rev Española Enfermedades Dig. 2012;104(11):617–618.
   PubMed Web of Science ®Google Scholar
• Gómez-Lumbreras A, Marcos-Fosch C, Aguilera C. Psychotropic drugs and liver toxicity. Am J Ther. 2018;25(5):e601–e602.
   PubMed Web of Science ®Google Scholar
• Yandrapalli S, Malik A, Guber K, et al. Statins and the potential for higher diabetes mellitus risk. Expert Rev Clin Pharmacol. 2019;12(9):825–830.
   PubMed Web of Science ®Google Scholar
• Pillinger T, McCutcheon RA, Vano L, et al. Comparative effects of 18 antipsychotics on metabolic function in patients with schizophrenia, predictors of metabolic dysregulation, and association with psychopathology: a systematic review and network meta-analysis. Lancet Psychiatry. 2020;7(1):64–77.
   PubMed Web of Science ®Google Scholar
• De Hert M, Detraux J, van Winkel R, et al. Metabolic and cardiovascular adverse effects associated with antipsychotic drugs. Nat Rev Endocrinol. 2012;8(2):114–126.
   Web of Science ®Google Scholar
• Citrome L. A review of the pharmacology, efficacy and tolerability of recently approved and upcoming oral antipsychotics: an evidence-based medicine approach. CNS Drugs. 2013;27(11):879–911.
   PubMed Web of Science ®Google Scholar
• Corponi F, Fabbri C, Bitter I, et al. Novel antipsychotics specificity profile: a clinically oriented review of lurasidone, brexpiprazole, cariprazine and lumateperone. Eur Neuropsychopharmacol. 2019;29(9):971–985.
   PubMed Web of Science ®Google Scholar
• Blair HA. Lumateperone: first Approval. Drugs. 2020;80(4):417–423.
   PubMed Web of Science ®Google Scholar
• Sabatine MS. PCSK9 inhibitors: clinical evidence and implementation. Nat Rev Cardiol. 2019;16(3):155–165.
   PubMed Web of Science ®Google Scholar
• Kosoglou T, Statkevich P, Johnson-Levonas AO, et al. Ezetimibe. Clin Pharmacokinet. 2005;44(5):467–494.
   PubMed Web of Science ®Google Scholar
• Barclay J, McCollum B, Schoretsanitis G, et al. Gemfibrozil may decrease norclozapine elimination. J Clin Psychopharmacol. 2019;39(4):405–407.
   PubMed Web of Science ®Google Scholar
• Arulmozhi DK, Dwyer DS, Bodhankar SL. Antipsychotic induced metabolic abnormalities: an interaction study with various PPAR modulators in mice. Life Sci. 2006;79(19):1865–1872.
   PubMed Web of Science ®Google Scholar
• Franco JM, Vallabhajosyula S, Griffin TJ. Quetiapine-induced hypertriglyceridaemia causing acute pancreatitis. Case Rep. 2015;2015:bcr2015209571–bcr2015209571.
   Google Scholar
• American Diabetes Association. Addendum. Pharmacologic approaches to glycemic treatment: standards of medical care in diabetes—2020 . Diabetes Care. 2020;43(Suppl. 1):S98–S110. Diabetes Care. 2020;43:1979–1979.
   PubMedGoogle Scholar
• Lally J, O’ Loughlin A, Stubbs B, et al. Pharmacological management of diabetes in severe mental illness: a comprehensive clinical review of efficacy, safety and tolerability. Expert Rev Clin Pharmacol. 2018;11(4):411–424.
   PubMed Web of Science ®Google Scholar
• DeGorter MK, Xia CQ, Yang JJ, et al. Drug transporters in drug efficacy and toxicity. Annu Rev Pharmacol Toxicol. 2012;52(1):249–273.
   PubMedGoogle Scholar
• Nath M, Bhattacharjee K, Choudhury Y. Pleiotropic effects of anti-diabetic drugs: a comprehensive review. Eur J Pharmacol. 2020;884:173349.
   PubMed Web of Science ®Google Scholar
• Papachristou S, Papanas N. Reduction of depression in diabetes: a new pleiotropic action of metformin? Diabetes Ther. 2021;12(4):965–968.
   PubMed Web of Science ®Google Scholar
• Sunjaya AP, Sunjaya AF. Targeting ageing and preventing organ degeneration with metformin. Diabetes Metab. 2021;47(1):101203.
   PubMed Web of Science ®Google Scholar
• Inzucchi SE, Lipska KJ, Mayo H, et al. Metformin in patients with type 2 diabetes and kidney disease. JAMA. 2014;312(24):2668.
   PubMed Web of Science ®Google Scholar
• Lazarus B, Wu A, Shin J-I, et al. Association of metformin use with risk of lactic acidosis across the range of kidney function. JAMA Intern Med. 2018;178(7):903.
   PubMed Web of Science ®Google Scholar
• Kamber N, Davis WA, Bruce DG, et al. Metformin and lactic acidosis in an Australian community setting: the Fremantle diabetes study. Med J Aust. 2008;188(8):446–449.
   PubMed Web of Science ®Google Scholar
• Roussel R. Metformin use and mortality among patients with diabetes and atherothrombosis metformin use with diabetes and atherothrombosis. Arch Intern Med. 2010;170(21):1892.
   PubMedGoogle Scholar
• Ekström N, Schiöler L, Svensson A-M, et al. Effectiveness and safety of metformin in 51 675 patients with type 2 diabetes and different levels of renal function: a cohort study from the Swedish National Diabetes Register. BMJ Open. 2012;2(4):e001076.
   PubMed Web of Science ®Google Scholar
• Koren W, Kreis Y, Duchowiczny K, et al. Lactic Acidosis and fatal myocardial failure due to clozapine. Ann Pharmacother. 1997;31(2):168–170.
   PubMed Web of Science ®Google Scholar
• Vancampfort D, Firth J, Correll CU, et al. The impact of pharmacological and non‐pharmacological interventions to improve physical health outcomes in people with schizophrenia: a meta‐review of meta‐analyses of randomized controlled trials. World Psychiatry. 2019;18(1):53–66.
   PubMed Web of Science ®Google Scholar
• Williams DM, Nawaz A, Evans M. Sodium-Glucose Co-Transporter 2 (SGLT2) inhibitors: are they all the same? A narrative review of cardiovascular outcome trials. Diabetes Ther. 2021;12(1):55–70.
   PubMed Web of Science ®Google Scholar
• Schnell O, Cos X, Cosentino F, et al. Report from the CVOT Summit 2020: new cardiovascular and renal outcomes. Cardiovasc Diabetol. 2021;20(1):75.
   PubMed Web of Science ®Google Scholar
• Verma S, V MJJ. SGLT2 inhibitors and mechanisms of cardiovascular benefit: a state-of-the-art review. Diabetologia. 2018;61(10):2108–2117.
   PubMed Web of Science ®Google Scholar
• Zelniker TA, Wiviott SD, Raz I, et al. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet. 2019;393(10166):31–39.
   PubMed Web of Science ®Google Scholar
• Williams DM, Nawaz A, Evans M. Renal outcomes in type 2 diabetes: a review of cardiovascular and renal outcome trials. Diabetes Ther. 2020;11(2):369–386.
   PubMed Web of Science ®Google Scholar
• Lalagkas P-N, Poulentzas G, Kontogiorgis C, et al. Potential drug-drug interaction between sodium-glucose co-transporter 2 inhibitors and statins: pharmacological and clinical evidence. Expert Opin Drug Metab Toxicol. 2021;17(6):697–705.
   PubMed Web of Science ®Google Scholar
• Hurren KM, Pinelli NR. Drug-drug interactions with glucagon-like peptide-1 receptor agonists. Ann Pharmacother. 2012;46(5):710–717.
   PubMed Web of Science ®Google Scholar
• Polidori D, Sha S, Mudaliar S, et al. Canagliflozin lowers postprandial glucose and insulin by delaying intestinal glucose absorption in addition to increasing urinary glucose excretion: results of a randomized, placebo-controlled study. Diabetes Care. 2013;36(8):2154–2161.
   PubMed Web of Science ®Google Scholar
• Górriz JL, Soler MJ, Navarro-González JF, et al. GLP-1 receptor agonists and diabetic kidney disease: a call of attention to nephrologists. J Clin Med. 2020;9(4):947.
   PubMed Web of Science ®Google Scholar
• Siskind D, Hahn M, Correll CU, et al. Glucagon-like peptide-1 receptor agonists for antipsychotic-associated cardio-metabolic risk factors: a systematic review and individual participant data meta-analysis. Diabetes Obes Metab. 2019;21(2):293–302.
   PubMed Web of Science ®Google Scholar
• Jain AB, Ali A, Gorgojo Martínez JJ, et al. Switching between GLP‐1 receptor agonists in clinical practice: expert consensus and practical guidance. Int J Clin Pract. 2021;75(2). DOI:10.1111/ijcp.13731.
   Web of Science ®Google Scholar
• Ifteni P, Correll CU, Nielsen J, et al. Rapid clozapine titration in treatment-refractory bipolar disorder. J Affect Disord. 2014;166:168–172.
   PubMed Web of Science ®Google Scholar
• Masuda T, Misawa F, Takase M, et al. Association with hospitalization and all-cause discontinuation among patients with schizophrenia on clozapine vs other oral second-generation antipsychotics. JAMA Psychiatry. 2019;76(10):1052.
   PubMed Web of Science ®Google Scholar
• Nielsen J, Correll CU, Manu P, et al. Termination of clozapine treatment due to medical reasons. J Clin Psychiatry. 2013;74(6):603–613.
   PubMed Web of Science ®Google Scholar
• Manu P, Lapitskaya Y, Shaikh A, et al. Clozapine rechallenge after major adverse effects: clinical guidelines based on 259 cases. Am J Ther. 2018;25(2):e218–e223.
   PubMed Web of Science ®Google Scholar
• Rodriguez V, Hanley K, Arias AJ, et al. Successful clozapine rechallenge following recurrent clozapine-associated pancreatitis: a case report. BMC Pharmacol Toxicol. 2020;21(1):35.
   PubMed Web of Science ®Google Scholar
• Masharanim M, Kroon LC. Pancreatic hormones & glucose-lowering drugs. In: editors, Katzung B, Vanderah T. Basic & Clinical Pharmacology. 15th ed. New York: McGraw Hill; 2021. p. 1–38.
   Google Scholar
• Tkáč I, Raz I. Combined analysis of three large interventional trials with gliptins indicates increased incidence of acute pancreatitis in patients with type 2 diabetes. Diabetes Care. 2017;40:284–286.
   PubMed Web of Science ®Google Scholar
• Dicembrini I, Montereggi C, Nreu B, et al. Pancreatitis and pancreatic cancer in patients treated with dipeptidyl peptidase-4 inhibitors: an extensive and updated meta-analysis of randomized controlled trials. Diabetes Res Clin Pract. 2020;159:107981.
   PubMed Web of Science ®Google Scholar
• Moghimi Sarani E, Memari E, Anushiravani A, et al. Is sitagliptin effective for modulating metabolic disturbances associated with olanzapine in schizophrenia patients? A double-blind placebo-controlled clinical trial. J Clin Psychopharmacol. 2020;40(5):487–490.
   PubMed Web of Science ®Google Scholar
• Sola D, Rossi L, Schianca GPC, et al. Sulfonylureas and their use in clinical practice. Arch Med Sci. 2015;11:840–848.
   PubMed Web of Science ®Google Scholar
• Maruthur NM, Tseng E, Hutfless S, et al. Diabetes medications as monotherapy or metformin-based combination therapy for type 2 diabetes: a systematic review and meta-analysis. Ann Intern Med. 2016;164(11):740–751.
   PubMed Web of Science ®Google Scholar
• Lean MEJ, Pajonk F-G. Patients on atypical antipsychotic drugs. Diabetes Care. 2003;26(5):1597–1605.
   PubMed Web of Science ®Google Scholar
• Malek R, Davis SN. Pharmacokinetics, efficacy and safety of glyburide for treatment of gestational diabetes mellitus. Expert Opin Drug Metab Toxicol. 2016;12(6):691–699.
   PubMed Web of Science ®Google Scholar
• Derosa G, Maffioli P. Mini-special issue paper management of diabetic patients with hypoglycemic agents α-glucosidase inhibitors and their use in clinical practice. Arch Med Sci. 2012;5:899–906.
   Google Scholar
• Van de Laar FA, Lucassen PLBJ, Akkermans RP, et al. Alpha-glucosidase inhibitors for type 2 diabetes mellitus. Cochrane Database Syst Rev. 2005;2009(2):CD003639.
   Google Scholar
• Markham A. Setmelanotide: first approval. Drugs. 2021;81(3):397–403.
   PubMed Web of Science ®Google Scholar
• Wang Y, Wang D, Cheng J, et al., Efficacy and tolerability of pharmacological interventions on metabolic disturbance induced by atypical antipsychotics in adults: a systematic review and network meta-analysis. J Psychopharmacol. 2021;35(9):1111–1119.
   PubMed Web of Science ®Google Scholar
• Barboza JJ, Huamán MR, Melgar B, et al. Efficacy of liraglutide in non-diabetic obese adults: a systematic review and meta-analysis of randomized controlled trials. J Clin Med. 2022;11(11):2998.
   PubMed Web of Science ®Google Scholar
• Arastu N, Cummins O, Uribe W, et al. Efficacy of subcutaneous semaglutide compared to placebo for weight loss in obese, non-diabetic adults: a systematic review & meta-analysis. Int J Clin Pharm. 2022;44(4):852–859.
   PubMed Web of Science ®Google Scholar
• Cignarella A, Busetto L, Vettor R. Pharmacotherapy of obesity: an update. Pharmacol Res. 2021;169:105649.
   PubMed Web of Science ®Google Scholar
• Varma S, Bishara D, Besag FMC, et al. Clozapine-related EEG changes and seizures: dose and plasma-level relationships. Ther Adv Psychopharmacol. 2011;1(2):47–66.
   PubMedGoogle Scholar
• Dean L. Thioridazine Therapy and CYP2D6 Genotypes. In: Pratt V, Scott S, Pirmohamed M, editors. Med. Genet. Summ. Bethesda (MD): National Center for Biotechnology Information (US); 2012. p. 1–8.
   Google Scholar
• Tek C, Ratliff J, Reutenauer E, et al. A randomized, double-blind, placebo-controlled pilot study of naltrexone to counteract antipsychotic-associated weight gain. J Clin Psychopharmacol. 2014;34(5):608–612.
   PubMed Web of Science ®Google Scholar
• Silverman BL, Martin W, Memisoglu A, et al. A randomized, double-blind, placebo-controlled proof of concept study to evaluate samidorphan in the prevention of olanzapine-induced weight gain in healthy volunteers. Schizophr Res. 2018;195:245–251.
   PubMed Web of Science ®Google Scholar
• Martin WF, Correll CU, Weiden PJ, et al. Mitigation of olanzapine-induced weight gain with samidorphan, an opioid antagonist: a randomized double-blind phase 2 study in patients with schizophrenia. Am J Psychiatry. 2019;176(6):457–467.
   PubMed Web of Science ®Google Scholar
• Correll CU, Newcomer JW, Silverman B, et al. Effects of olanzapine combined with samidorphan on weight gain in schizophrenia: a 24-week phase 3 study. Am J Psychiatry. 2020;177(12):1168–1178.
   PubMed Web of Science ®Google Scholar
• Tchoukhine E, Takala P, Hakko H, et al. Orlistat in clozapine- or olanzapine-treated patients with overweight or obesity. J Clin Psychiatry. 2011;72(3):326–330.
   PubMed Web of Science ®Google Scholar
• Carli M, Kolachalam S, Longoni B, et al. Atypical antipsychotics and metabolic syndrome: from molecular mechanisms to clinical differences. Pharmaceuticals. 2021;14(3):238.
   Web of Science ®Google Scholar
• Huhn M, Nikolakopoulou A, Schneider-Thoma J, et al. Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis. Lancet. 2019;394(10202):939–951.
   PubMed Web of Science ®Google Scholar
• Kane JM, Durgam S, Satlin A, et al. Safety and tolerability of lumateperone for the treatment of schizophrenia: a pooled analysis of late-phase placebo- and active-controlled clinical trials. Int Clin Psychopharmacol. 2021;36(5):244–250.
   PubMed Web of Science ®Google Scholar
• Newcomer JW. Metabolic considerations in the use of antipsychotic medications: a review of recent evidence. J Clin Psychiatry. 2007;68(Suppl 1):20–27.
   PubMed Web of Science ®Google Scholar
• Hirsch L, Yang J, Bresee L, et al. Second-generation antipsychotics and metabolic side effects: a systematic review of population-based studies. Drug Saf. 2017;40(9):771–781.
   PubMed Web of Science ®Google Scholar
• Højlund M, Andersen K, Ernst MT, et al. Use of low‐dose quetiapine increases the risk of major adverse cardiovascular events: results from a nationwide active comparator‐controlled cohort study. World Psychiatry. 2022;21(3):444–451.
   PubMed Web of Science ®Google Scholar
• Højlund M, Lund LC, Andersen K, et al. Association of low-dose quetiapine and diabetes. JAMA Network Open. 2021;4(5):e213209.
   PubMed Web of Science ®Google Scholar
• Brugger SP, Howes OD. Heterogeneity and homogeneity of regional brain structure in schizophrenia. JAMA Psychiatry. 2017;74:1104.
   PubMed Web of Science ®Google Scholar
• Correll CU, Rubio JM, Kane JM. What is the risk-benefit ratio of long-term antipsychotic treatment in people with schizophrenia? World Psychiatry. 2018;17(2):149–160.
   PubMed Web of Science ®Google Scholar
• Levitt P, Ebert P, Mirnics K, et al. Making the case for a candidate vulnerability gene in schizophrenia: convergent evidence for regulator of G-protein signaling 4 (RGS4). Biol Psychiatry. 2006;60(6):534–537.
   PubMed Web of Science ®Google Scholar
• Campbell DB, Levitt P. Future of individualized psychiatric treatment. Pharmacogenomics. 2008;9(5):493–495.
   PubMed Web of Science ®Google Scholar
• Zhang J-P, Lencz T, Zhang RX, et al. Pharmacogenetic associations of antipsychotic drug-related weight gain: a systematic review and meta-analysis. Schizophr Bull. 2016;42(6):1418–1437.
   PubMed Web of Science ®Google Scholar
• Saiz-Rodríguez M, Almenara S, Navares-Gómez M, et al. Effect of the most relevant CYP3A4 and CYP3A5 polymorphisms on the pharmacokinetic parameters of 10 CYP3A substrates. Biomedicines. 2020;8(4):94.
   PubMed Web of Science ®Google Scholar
• Olfson M, King M, Schoenbaum M. Antipsychotic Treatment of Adults in the United States. J Clin Psychiatry. 2015;76(10):1346–1353.
   PubMed Web of Science ®Google Scholar
• Krogmann A, Peters L, von Hardenberg L, et al. Keeping up with the therapeutic advances in schizophrenia: a review of novel and emerging pharmacological entities. CNS Spectr. 2019;24(S1):38–69.
   PubMedGoogle Scholar
• Correll C, Solmi M, Cortese S, et al. The future of psychopharmacology: a critical appraisal of ongoing phase 2/3 trials, and of some trends aiming to de-risk trial programmes of novel agents. World Psychiatry; 2023.
   Google Scholar
• Huang J, Xiao J, Peng Z, et al. PCSK9 mediates dyslipidemia induced by olanzapine treatment in schizophrenia patients. Psychopharmacology (Berl). 2022;239(1):83–91.
   PubMed Web of Science ®Google Scholar
• Lamb YN. Inclisiran: first Approval. Drugs. 2021;81(3):389–395.
   PubMed Web of Science ®Google Scholar
• Catapano AL, Pirillo A, Norata GD. New pharmacological approaches to target PCSK9. Curr Atheroscler Rep. 2020;22(7):24.
   PubMed Web of Science ®Google Scholar
• Manu P, Dima L, Shulman M, et al. Weight gain and obesity in schizophrenia: epidemiology, pathobiology, and management. Acta Psychiatr Scand. 2015;132(2):97–108.
   PubMed Web of Science ®Google Scholar